Kornimate/medical-research-clean huggingface dataset:
iron deficiency anemia in childern with liver cirrhosis

Conditions: Iron Deficiency, Anaemia in Children; Liver Cirrhosis

Summary: iron deficiency anemia is a common complication of liver cirrhosis in childern and may affects there life this study to improve the outcome of these patients

patients with cirrhosis are at risk of developing both ida and anemia of chronic disease concomitantly, and there adverse effects can deteriorate general condition and affect of quality of life in these patients .also because it is easier to correct ida than anemia of chronic disease, so this study of the prevalence of ida helping us in the diagnosis and treatment of ida and can reduce the need for other diagnostic tests and improve the quality of life in patients with cirrhosis .

Eligibility criteria:
inclusion criteria: * all childern with liver cirrhosis in git and hepatology unit exclusion criteria: * neonates less than one month * childern with other liver diseases
the effectiveness of the water jet device in removing dental plaque around orthodontic braces in adolescents

Conditions: Plaque, Dental

Summary: the aim of this study was to evaluate the effectiveness of the water jet in removing dental plaque around the orthodontic braces in adolescents.

the aim of this randomized controlled trial was to evaluate the effectiveness of the water jet in removing dental plaque around the orthodontic braces compared to manual toothbrush in adolescents. the null hypothesis was that no significant difference would be noted between the water jet and manual toothbrush in removing dental plaque around the orthodontic braces. such studies provide another dental care tools for maintaining oral hygiene among orthodontic patients.

Eligibility criteria:
inclusion criteria: 1. healthy children. 2. children aged 11 to 15 years. 3. children who did not receive any fluoride treatment in the dental clinic. 4. patients who had orthodontic braces at least on the anterior segment of the upper and lower jaws. exclusion criteria: 1. special health care needs (shcn) patients.
automated telephone nutrition support

Conditions: Diabetes Mellitus

Summary: the automated telephone nutrition support (atns) study investigates the effect of automated telephone nutrition support on diet and glycemic control among spanish-speaking diabetics in oakland.

the automated telephone nutrition support (atns) study is a joint effort between the university of california at san francisco, la clinica de la raza, and patients living with diabetes in fruitvale (oakland). our goal is to see if motivated people with diabetes are able to get their blood sugar under better control by choosing a healthier diet. since it's hard to eat a healthy diet, one of the ways we are trying to help is by calling people, having them record what they've eaten, and reminding them of the right foods to eat. the innovative part is using an automated telephone system to call them to have them record their dietary choices and giving them feedback immediately regarding what to modify as appropriate.

Eligibility criteria:
inclusion criteria: * age \>18. * diabetic with a1c \>8.5 for at least 1 year based on clinic records. * spanish-speaking (self-defined) exclusion criteria: * no telephone at home * planning to be out of town for longer than 2 weeks in the coming 12 weeks and thus unable to take part in follow up * pregnancy * insulin-dependent diabetes * any evidence of end organ damage including chronic kidney disease requiring dialysis, congestive heart failure, or cirrhosis.

Keywords: diabetes mellitus telephone nutrition support automated low english proficiency hispanic latino
promoting development in toddlers with communication delays

Conditions: Autism Spectrum Disorder

Summary: eighty parent-child dyads will be recruited and randomly assigned to either the experimental intervention or an active control condition. subjects assigned to the experimental group will participate in 12 home-based intervention sessions.

the experimental intervention is manualized, follows an illustrated workbook for parents, and uses individualized video-feedback, modeling, and coaching strategies to help parents establish play interactions that promote communication. all participants take part in comprehensive baseline and post-intervention/post-active control assessments, as well as 6- and 12-month follow up assessments. families in the active control group will also be invited to participate in an oral feedback session to discuss the results from these assessments. children's involvement in other forms of intervention will be monitored using a validated intervention log so that the moderating effects of these treatments can be examined. by targeting parent-child interactions, the current intervention ensures that new child behaviors generalize beyond the immediate context of the intervention and are maintained over time (schreibman, 2000). in addition, by involving parents in the treatment of their children (e.g., by establishing a daily playtime routine), the current intervention ensures that the intervention strategies are implemented with sufficient intensity for causing developmental change (national research council, 2001).

Eligibility criteria:
inclusion criteria: * the child is between 15 and 30 months of age; * the child scores at least one standard deviation below average on the social composite score of the csbs dp. exclusion criteria: * the child has been diagnosed with a known medical condition that has been linked to either autism or mental retardation (e.g., fragile x, tuberous sclerosis, cerebral palsy, hydrocephalus). * the child has a severe visual, hearing, or motor impairment or fragile health condition that would prevent him/her from validly participating in the assessment procedures.

Keywords: maternal synchrony parent-child parent child play social communication
comparison of staples versus subcuticular suture in class iii obese women undergoing cesarean delivery

Conditions: Obesity, Severe; Cesarean Section

Summary: the purpose of this study is to determine the optimal skin closure technique (staples versus subcuticular suture) at the time of cesarean delivery in class iii obese women with body mass index (bmi) of \>/= 40kg/m2.

a. to assess the rate of wound complications with staples versus subcuticular suture closure in women with a bmi of ≥ 40 kg/m2 undergoing cesarean delivery (cd). b. no difference was observed in wound complication rates between staples and subcuticular suture skin closure in women with a bmi ≥ 40 kg/m2 undergoing cesarean delivery (cd). c. at this time, optimal skin closure method in obese women with bmi ≥ 40 kg/m2 undergoing cesarean delivery remains unknown. more work is needed in this area to help reduce the complication rate in this very high-risk population.

Eligibility criteria:
inclusion criteria: 1. women \> 18 years old undergoing cesarean delivery (cd) 2. bmi of \>/= 40 kg/m2 as determined by height and weight reported during their admission 3. live gestation 23 weeks or greater 4. women who are able to follow-up 7-14 days after hospital discharge for a visual wound check. exclusion criteria: 1. active lupus flare 2. hiv/aids 3. current treatment for cancer or h/o radiation to the abdomen/pelvis 4. hypersensitivity to steri-strips
a study of gfh375 in patients with advanced solid tumors with kras g12d mutations

Conditions: KRAS G12D Mutations; Advanced Solid Tumors

Summary: this is a multicenter, open-label, phase i/ii study to explore the safety, tolerability, pharmacokinetics (pk), and preliminary efficacy of gfh375 in patients with advanced solid tumors harboring a kras g12d mutation.


Eligibility criteria:
inclusion criteria: 1. subjects must voluntarily agree to participate in the trial and sign a written informed consent form. 2. male or female ≥ 18 years old and ≤75 years old. 3. ecog performance status of 0-1. 4. with a life expectancy of ≥12 weeks. 5. with histologically or cytologically confirmed advanced or metastatic solid tumors harboring kras g12d mutation. 6. have at least one measurable lesion according to recist1.1, and the phase ia allows no measurable lesion. 7. adequate laboratory parameters during the screening period. exclusion criteria: 1. active brain metastases. 2. prior treatment with a kras g12d inhibitor. 3. palliative radiotherapy was completed within 14 days before the first dose. 4. have poorly controlled or severe cardiovascular disease. 5. subjects with active hepatitis b or active hepatitis c. 6. known allergy to the study drug or its components. 7. pregnant or lactating women.
treatment of dural arteriovenous fistulas with squid™ liquid embolic agent

Conditions: Dural Arteriovenous Fistula

Summary: the purpose of this study is assessment of safety, efficacy, and short-term outcome of squid™ in the embolization of dural arteriovenous fistula

traditionally, there are two therapeutic options for the treatment of dural arteriovenous fistula (davf): (1) the surgical approach consisting of craniotomy and ligation of the vein and (2) the endovascular approach with embolization of shunting zone. onyx™ (evoh (ethylene vinyl alcohol) in solution in an organic solvent, dmso (dimethyl sulfoxide), is the main embolic agent used for the endovascular treatment of davf. during the occlusion procedure with onyx™, residual malformed compartments become gradually less visible on x-ray to the operator, due to the high radiopacity of onyx™, resulting in a potential risk during treatment. moreover, viscosity is frequently not as low as required to penetrate the shunt.thus, development a new embolization system with lower radiopacity and lower viscosity to achieve improved occlusion is needed. squid™ is a new liquid embolic agent, with variable radiopacity and viscosity. the purpose of this study is assessment of safety, efficacy, and short-term outcome of squid™ in the embolization of davfs .

Eligibility criteria:
inclusion criteria: * dural arteriovenous fistula requiring endovascular treatment with a lariboisiere score between 3 - 5 * intended usage of squid™ * the patient agrees with the clinical data collection and medical file access. exclusion criteria: * davf with a lariboisiere score \< 3 • pregnancy

Keywords: endovascular treatment liquid embolization
skin decolonization of children hospitalized in intensive care unit

Conditions: Central Venous Catheter

Summary: the purpose of this study is to evaluate the efficacy and duration of the skin decolonization brought by a daily wash using chlorhexidine gluconate 2% pad compared to a standard wash with mild soap in children hospitalized in intensive care unit.

skin is a major reservoir of pathogenic bacteria and intensive care unit patients are particularly vulnerable to variations in skin colonization and so to infections. these bacterial skin colonizations can contaminate other patients, nursing staff or even samples, but above all they are an endogenous source of infection of material. these bacterial skin colonizations hold therefore a major place in the responsibility of infections associated with care and can potentially affect the length of patient hospitalization. 2% chlorhexidine gluconate pads have already demonstrated a real efficacy in the sustainable reduction of central venous catheter-related bacteremias in adults and in children, probably through a reduction of cutaneous microbial colonization. however, this hypothesis remains to be confirmed. patients in the pediatric surgical intensive care unit of necker-enfants malades hospital are minors, hospitalized in critical and continuous surgical surveillance unit, for all surgical specialties excluding cardiac surgery. the use of central venous catheters concerns approximately 60% of the hospitalization days identified each year. to control catheter-related bacteremias, all intensive care unit patients are subjected to a service protocol since 2015, which defines a mild soap daily wash in patients without central venous catheter and a wash with chlorhexidine in patients with central venous catheter. successive standardized samples will be carried out on the skin of the children submissive to both types of washes during their hospitalization in intensive care unit.

Eligibility criteria:
inclusion criteria: * patients from 0 to 17 years old * hospitalized in the pediatric surgical intensive care unit of the necker hospital for a duration of at least 5 days * patients likely to receive the 2 types of washes (mild soap and chlorhexidine gluconate ) * patients subject to the service wash protocol for at least two daily washes (24 hours) exclusion criteria: * patients not following the 2 types of washes * chronic skin lesions * refusal to participate expressed by the holders of the parental authority and/or patient * not respecting the 24h imposed for each wash

Keywords: central venous catheter-related bacteremias skin decolonization intensive care unit hospitalization
effects of insulin detemir and nph insulin on renal handling of sodium, fluid retention, and weight in type 2 diabetic patients

Conditions: Diabetes Type 2; Weight Gain

Summary: hypothesis: changing type 2 patients treatment from insulin insulatard to insulin detemir will increase their excretion of sodium in the urine and thereby decrease their extracellular volume and body weight. 24 patients are divided into 2 groups and their insulin treatment is shifted while their body composition, sodium excretion, weight and extracellular volume is monitored.

type 2 diabetic patients experience weight gain when receiving insulin treatment. there has been reports that the weight gain is less or absent when patients are treated with insulin detemir. patients with diabetes have increased total body sodium and increased extracellular volume. we hypothesize that part of the weight gain seen is due to increase in extracellular volume and that the lesser weight gain seen in patients treated with detemir is due to an lesser increase in extracellular volume. we believe that the cause of this difference is the different pharmacokinetic properties of insulin detemir. insulin detemir i protein bound and is therefore not excreted in the kidneys. this may cause less sodium reabsorption, than with other insulins, and therefore less increase in extracellular volume. we test this hypothesis by examining urinary sodium excretion, extracellular volume by gfr measurements, body composition by dexa scan, body weight, and 24 hour blood pressure.in patients that are changed from insulin insulatard to insulin detemir and back.

Eligibility criteria:
inclusion criteria: * type 2 diabetes according to who 1999 criteria for at least 3 month * insulin treated for at least 1 month * bmi 25-40 * age 18-80 * hb1ac \< 10% exclusion criteria: * hypertension not well regulated * serum creatinine \> 130 micromol/l * non-diabetic kidney disease * disease that may cause invalid hgba1c measurement * substance abuse * recent use of detemir * pregnancy or risk of becoming pregnant * any condition that may disturb protocol adherence (language barrier etc) urinary albumin \> 30 mg/24hours ( before screening) * use of drugs that may influence blood glucose (except oral antidiabetics) * use of drugs that may influence sodium balance,i.e diuretics ( tiazides accepted) * clinical significant disease that may influence outcome ( cancer etc)

Keywords: weight gain in insulin treated type 2 diabetes extracellular volume insulin treatment sodium retention
long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy in patients with major depressive disorder

Conditions: Major Depressive Disorder

Summary: the objective of this study is to evaluate the long-term safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (adt) in patients with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * patients who have provided consent prior to any study specific procedures * meets the diagnostic and statistical manual of mental disorders, 4th edition, text revision (dsm-iv-tr) criteria for mdd * new patients must have ongoing inadequate response to protocol allowed adts as reported in antidepressant treatment response questionnaire (atrq) * for rollover patients from rgh-md-72 \[nct01715805\], completion of study rgh-md-72 (either double-blind or single-blind treatment periods) with continued adt treatment. exclusion criteria: * patients who do not meet the dsm-iv-tr criteria for mdd.

Keywords: major depressive disorder mdd depression
the role of timed awakening in treatment of enuresis

Conditions: Nocturnal Enuresis; Voiding Dysfunction

Summary: the goal of this clinical trial is to evaluate the effectiveness of nightly timed awakening in the treatment of nocturnal enuresis in children aged 6-17. the main questions it aims to: * determine feasibility of nightly timed awakenings * determine the role, if any, of comorbidities on resolution of enuresis * determine incidence of daytime accidents * obtain patient and parental satisfaction scores researchers will compare a control group to treatment groups to see if there is any impact on nocturnal enuresis. participants will be woken up by parents in the middle of the night to use the restroom. in addition, participants will receive 30 minute psychotherapy sessions using telehealth.


Eligibility criteria:
inclusion criteria: * our inclusion criteria are new and recently evaluated (within past 6 months) patients who are english-speaking * aged 6-17 * referred to the urology clinic for enuresis (enuresis in our study is defined as nocturnal or diurnal enuresis (more than 1 bedwetting episode/week) for greater than 3 months) exclusion criteria: * diagnosis of enuresis with comorbid diagnosis of diabetes mellitus (type 1 and 2), diabetes insipidus, chronic kidney disease, polyuria and/or polydipsia * structural urologic disease (evaluated via baseline imaging) * diagnosis of neurodevelopmental delays or conditions (i.e. celebral palsy, autism spectrum disorder) that hinders inability to follow age-appropriate instructions * not potty trained * improved or resolved enuresis for patients recently evaluated (within the past 6 months) * non-english speaking * patients currently on any over-active-bladder (oab) medications (b3- agonists, antichloingerics) or alpha blockers for urinary symptoms (i.e. alfuzosin, tamsulosion, etc) or anti-diurectic medications for urinary symptoms (i.e.: desmopression (ddavp)) * patients currently using bed-wetting alarms * patients and families who are actively seeing pediatric clinical urologic psychologist. * inability or unwillingness of individual or legal guardian/representative to give written informed consent or participate in the study

Keywords: lifting incontinence bedwetting
evaluation of the gore® viabahn® endoprosthesis for the treatment of popliteal artery aneurysm (paa)

Conditions: Popliteal Artery Aneurysm

Summary: this study will assess the long term safety and performance of the gore® viabahn® endoprosthesis for the treatment of patients with popliteal artery aneurysms.


Eligibility criteria:
inclusion criteria: inclusion to the study requires the patient: 1. received a gore® viabahn® endoprosthesis to treat a popliteal artery aneurysm 2. had a symptomatic aneurysm or asymptomatic aneurysm (≥ 2 cm diameter) of the popliteal artery, or the presence of mural thrombus (\< 2 cm) in the popliteal artery; 3. was 18 years of age or older at the time of the treatment; 4. had an elective popliteal artery aneurysm procedure; 5. has provided informed consent, personally or through lawful representation as determined by applicable local regulations and state law exclusion criteria: prior to or at the time of implant the patient is / has: 1. bilateral popliteal artery aneurysms with initial treatment on the same day; 2. thrombotic occlusion of the popliteal artery or paa; 3. marfan syndrome or ehlers-danlos syndrome; 4. unable to tolerate antiplatelet therapy; 5. thrombophilia requiring long term anticoagulation; 6. known allergies to the gore® viabahn® endoprosthesis components; 7. enrolled in another investigational drug or medical device trial where participation may have affected the outcome or treatment of the subject in the popliteal artery aneurysm study with the gore® viabahn® endoprosthesis or had previous surgery for the popliteal artery aneurysm in the study limb.
an open-label, long-term extension study with filgotinib in active psoriatic arthritis.

Conditions: Psoriatic Arthritis

Summary: this is a phase 2, multicenter, open-label, single arm, long term extension (lte) safety, tolerability and efficacy study of filgotinib in subjects with moderately to severely active psa. it is estimated that approximately 105 subjects will be rolled-over after they have completed the 16 weeks of double-blind treatment in core study glpg0634-cl-224. subjects will be administered filgotinib in this study until filgotinib is registered for psa or until week 304, whichever occurs first. the lte study is concluded with a follow-up visit approximately 4 weeks after the last intake of study treatment.


Eligibility criteria:
inclusion criteria: * male or female subjects who are ≥18 years of age, having completed the 16 weeks of treatment in the qualifying core study glpg0634-cl-224 and who may benefit from filgotinib long-term treatment according to the investigator's judgment. * male and female subjects of childbearing potential who engage in heterosexual intercourse must agree to continue to use highly effective methods of contraception as described in the protocol. * able and willing to sign the informed consent form (icf), as approved by the independent ethics committee (iec) and agree to the schedule of assessments. exclusion criteria: * subjects who are deemed not to be benefitting from the study drug based upon lack of improvement or worsening of their symptoms. local guidelines for subject treatment need to be followed. * persistent abnormal laboratory values associated with the use of the study drug (including and not limited to hematology, liver and renal function values), according to the investigator's clinical judgment. * subjects who discontinued the qualifying core study glpg0634-cl-224 due to safety or tolerability issues. * subjects who require immunization with live/live attenuated vaccine. * diagnosis of rheumatic autoimmune disease or inflammatory joint disease other than psoriatic arthritis, except for sjögren's syndrome. * subjects with symptoms suggestive of uncontrolled hypertension, congestive heart failure, uncontrolled diabetes, cerebrovascular accident, myocardial infarction, unstable angina, unstable arrhythmia or any other cardiovascular condition since the inclusion to the glpg0634- cl-224 study. * subjects with symptoms suggestive of gastrointestinal tract ulceration and/or active diverticulitis since the inclusion to the glpg0634-cl-224 study. * subjects with symptoms suggestive of possible lymphoproliferative disease including lymphadenopathy or splenomegaly since the inclusion to the glpg0634-cl-224 study. * subjects with symptoms suggestive of malignancy since the inclusion to the glpg0634-cl-224 study.